How does Scemblix (asciminib) treat chronic myeloid leukemia (CML)?
Scemblix (asciminib) treats CML by targeting the BCR-ABL1 driver that drives uncontrolled growth of leukemia cells. It inhibits the BCR-ABL1 tyrosine kinase, which reduces signaling that leukemia cells rely on to proliferate and survive.[1]
What is the difference between Scemblix and older CML drugs like dasatinib or imatinib?
Scemblix is a “STAMP” inhibitor that binds to an allosteric site on the BCR-ABL1 kinase (the ABL myristoyl pocket) rather than competing at the ATP-binding site used by many earlier tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or nilotinib.[1] This binding mode is designed to block the leukemia-driving kinase activity in a different way and can be useful in situations where resistance occurs to other TKIs.
How does BCR-ABL1 signaling contribute to CML?
CML is caused in most cases by the BCR-ABL1 fusion protein (from the Philadelphia chromosome). That fusion protein’s kinase activity sends signals that promote cell growth and survival. By inhibiting BCR-ABL1 kinase activity, Scemblix lowers those downstream growth signals, helping control the disease.[1]
When is Scemblix used in CML?
Scemblix is used for patients with CML who need BCR-ABL1 inhibition after earlier therapy, based on its approved clinical use.[1]
What do patients typically monitor while taking a BCR-ABL1 inhibitor?
Patients on CML TKIs are commonly monitored with regular blood and bone marrow testing for response (such as molecular response levels) and with safety monitoring for treatment-related adverse effects. Scemblix is still a BCR-ABL1–targeting therapy, so response monitoring follows the usual CML treatment approach.[1]
Source
[1] https://www.drugpatentwatch.com/drug/scemblix